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Abstract
We present the case of a 67-year-old male patient with a past history of previously resected T3
right adrenocortical carcinoma and T3N1 signet ring cell adenocarcinoma of the stomach who
presented with recurrence of gastric cancer in the form of a large solitary mass in the right
abdomen. He was treated with ECX (epirubicin, cisplatin and capecitabine) chemotherapy and
multivisceral resection. This recurrence pattern is the first such description in the literature,
and we discuss the controversies and arguments in favour of offering surgical resection.
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Introduction
Linitis plastica, also known as signet ring adenocarcinoma of the stomach, although rare but
rising in incidence, is associated with a poor prognosis and high recurrence rates following
surgical resection. It accounts for about 10% of all gastric cancers and is characterised by
rigidity and fibrotic thickening of the stomach wall. Standard treatment pathways are those of
gastric cancer, and surgical resection remains the only recognised therapeutic option offering a
potential cure. Recurrence is often in the form of disseminated peritoneal disease.
Case Presentation
We report the case of a 67-year-old retired consultant gastroenterologist with a past medical
history of primary hypothyroidism and past surgical history of a right adrenalectomy and
nephrectomy with inferior vena cava (IVC) resection in 2008 for a pT3 high-grade
adrenocortical carcinoma. Complete resection of the tumour was achieved microscopically with
free-floating tumour extension into the intrahepatic inferior vena cava. The tumour was
ruptured intraoperatively, and he was therefore advised to start long-term adjuvant mitotane.
This caused chronic adrenal insufficiency, treated with replacement therapy, and significant
hypercholesterolaemia. This is believed to have lead to a symptomatic superior mesenteric
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artery stenosis presenting in 2010, which was successfully treated with a superior mesenteric
artery stent.
In January 2012, he presented with melaena and was found to have a distal antral gastric
carcinoma, infiltrating submucosally, biopsies of which were consistent with linitis plastica. He
went on to have a subtotal gastrectomy, cholecystectomy, and D2 lymphadenectomy with neo-
adjuvant and adjuvant ECF chemotherapy (3 + 2 cycles). The 5-FU was replaced by raltitrexed
due to minor asymptomatic coronary disease and the sixth cycle was omitted as he moved to a
different region of the country. Histopathology showed a poorly differentiated diffuse type
adenocarcinoma of the antrum, staged as pT3 N1 (1/27) V0 R0, Mandard TRG 3. The mitotane
was stopped at the start of chemotherapy as no recurrence of the adrenocortical carcinoma was
evident on follow-up imaging. He remained well until August 2014 when he developed early
satiety and underwent gastroscopy, which showed no macroscopic abnormality, and random
biopsies from the staple line showed no malignancy. The patient presented again in October
2014 when he developed further abdominal pain. Computed tomography cross-axial imaging
showed a 14 cm mass around the ascending colon and hepatic flexure with a suspicion of
retroperitoneal and psoas involvement, as illustrated in Figure 1. Prior to the symptom-induced
imaging diagnosis of recurrence in October 2014, the previous adrenal follow-up imaging in
February of that year was reported as normal. Review, however, suggested that there may have
been an area of thickening in the wall of the colon at the hepatic flexure.
FIGURE 1: CT images showing mass centered on ascending
colon and hepatic flexure.
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A tunnelled transcolonic biopsy of this mass revealed the recurrence of the gastric
adenocarcinoma. Further imaging in the form of a PET scan in December 2014 showed
moderately FDG-avid (maximum SUV 9.2) wall thickening of the large bowel at the hepatic
flexure extending over a length of 10 cm, abutting the right psoas muscle; the uptake in the
muscle was thought to be physiological.
The case was discussed at the referring hospital's multi-disciplinary team meeting (MDT), and
he was offered six courses of palliative EOX chemotherapy. At the patient’s request, he was also
referred to our institution for a second opinion. He was subsequently seen in the oncology and
surgical clinics and discussed a number of times at our regional MDT. On review of further
imaging from March 2015, it was felt that the edge of the mass was not infiltrating the psoas
fascia and that the retroperitoneal fascia was intact, taking account of the postoperative
changes from his previous adrenal surgery. It was also noted that there was encasement around
the pancreas and focal dilatation of the distal common bile duct due to a mesenteric invasion,
although there was no significant derangement in liver function tests. Following extensive
discussion, the final suggestion was for the patient to be offered surgical resection after
completing six cycles of EOX (with no significant radiological response). Informed patient
consent was obtained. No identifying patient information is disclosed in this paper. 
On July 22, 2015, the patient underwent a right hemicolectomy with en bloc
pancreaticoduodenectomy, IVC resection, and retroperitoneal lymphadenectomy. The
histology reported that sections showed the presence of fibrosis in the wall of the colon and in
areas of adhesion between the large and small bowel. Within the fibrous area, there was an
uneven infiltrate of poorly differentiated adenocarcinoma with diffuse/signet ring
cell morphology. The carcinoma was present in the submucosa and muscularis propria of the
colon as well as the surrounding fibrous tissue of the adhesion, but there was no definite
lymphatic or venous invasion. No tumour was seen in the four lymph nodes identified and the
area of infiltration appeared completely excised. Immunohistochemistry highlighted that the
tumour also extended into the colonic mucosa, and was negative for HER2. The patient made
an uneventful recovery, interrupted only by admission with an intra-abdominal collection,
successfully treated with percutaneous drainage. Follow-up CT in November 2015 showed no
evidence of disease recurrence.
Discussion
Recurrence from gastric linitis plastica tumours is often in the form of the disseminated
peritoneal disease and standard treatment pathways are those of gastric adenocarcinoma.
However, there is increasing evidence that linitis plastica tumours of the stomach should be
considered a different disease entity from non-linitis plastica adenocarcinoma [1].
Furthermore, the optimal chemotherapeutic regimes are still controversial, as most studies do
not differentiate between linitis plastica and non-linitis plastica patient groups [2-3]. It is also
important to identify hereditary diffuse gastric cancer [4]. This patient has first and second
male cousins both diagnosed with breast cancer and his father had bowel cancer at the age of
72, but clinical genetics evaluation found no significant abnormalities.
It is clear that the timing and location of the lesion would have been more likely to represent a
recurrence of the adrenocortical carcinoma, and this highlights the importance of histological
confirmation. There are, moreover, several atypical features of this pattern of linitis plastica
recurrence that should be highlighted. As mentioned, review of earlier imaging suggested that
there might have been an area of thickening in the wall of the colon at the hepatic flexure prior
to the detection of the mass. This suggests that the recurrent lesion may have started in the
colon rather than the retroperitoneum (as supported by the postoperative histology). Secondly,
the presence of a large mass after only eight months without any obvious other sites of disease
2015 Sodergren et al. Cureus 7(12): e424. DOI 10.7759/cureus.424 3 of 5
is not a characteristic pattern of recurrence for linitis plastica tumours. For haematogenous
metastases of linitis plastica, there is no proven role for surgery, and this was the justification
for the treatment recommendation from the referring hospital, which in itself appears
evidence-based. In this case, however, there was no evident disease in more proximal sites for
the haematogenous spread, such as the liver or lung, raising the question of whether this
represented a local recurrence. The fact that the recurrence was solitary and had remained
solitary for a reasonable period of time, in addition to the atypical location for this histological
tumour type, were significant factors contributing to the decision to offer surgical resection. A
final interesting consideration in this case, although less likely, is whether this tumour could
represent a third primary, as primary linitis plastica of the colon has been reported [5]. The
patient, in his own right a specialist in this pathology having completed a career in clinical
gastroenterology, recognised certain anomalies and requested a second opinion. Nevertheless,
the decision to proceed to surgical resection was not straightforward and our MDT recognised
that there was a chance that it might not be technically possible to achieve an R0 resection or
that there would be peritoneal disease detected intra-operatively. It was felt that including a
multivisceral resection in the form of pancreaticoduodenectomy would be the best chance of
achieving a negative margin. At surgery, an en bloc inferior vena cava resection was performed,
as there were some thickening and nodular attachments from the main mass.
Conclusions
This specific recurrence pattern represents, to our knowledge, the first such case described in
the literature. The fact that surgical clearance required a major multivisceral resection with
significant potential morbidity, coupled with the uncertain efficacy of palliative chemotherapy,
highlights the dilemma faced by clinicians in advising the most appropriate treatment strategy.
All such cases should be discussed in a specialist MDT and any surgical intervention should be
reserved for patients who are fully informed of the available evidence base, morbidity profile
associated with the surgery, and rationale for such treatment.
Additional Information
Disclosures
Human subjects: Consent was obtained by all participants in this study.
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